Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393419 | 0.94 | ADORA2A (0.45) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393418 | 0.94 | ADORA2A (0.47) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393621 | 0.93 | ADORA2A (0.44) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393334 | 0.91 | ADORA2A (0.44) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393330 | 0.91 | ADORA2A (0.44) | ADORA2AADORA3ADORA1 | |
| SCHEMBL13625739 | 0.88 | ADORA2A (0.45) | ADORA2AADORA3ADORA1PIK3CDTLR9 | |
| SCHEMBL14393420 | 0.86 | ADORA2A (0.41) | ADORA2AADORA3ADORA1 | |
| SCHEMBL14393655 | 0.86 | ADORA2A (0.48) | ADORA2AADORA3ADORA1 | |
| SCHEMBL559647 | 0.84 | ADORA2A (0.48) | ADORA2AADORA3ADORA1PIK3CD | |
| SCHEMBL13626210 | 0.82 | ADORA2A (0.45) | ADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.